BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

When an insurance denial blocks guest writer Denise Schnieders from getting an MS disease activity test, she decides to fight back.

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...

Investigators have identified patients who tested positive for the Epstein-Barr Virus 9 years after they were diagnosed with MS, challenging the prevailing notion that the virus precedes MS.

Chennai: At 25, Bhanupriya was just another TNPSC aspirant from Madurai, preparing for her exams. One day, she lost partial ...